Drug Trial Radar · NCT04815720
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Aug 9, 2021
Primary completion
Jul 24, 2024
Study completion Jul 24, 2024
Sponsor
- Lead sponsor
- Vaccinex Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Interventions
pepinemab + pembrolizumabDrug
The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Treatment Emergent Adverse Events (TEAE's).Time frame: 2 Years
- Evaluation of RP2DTime frame: 2 Years
- Efficacy EndpointTime frame: 2 Years
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Highlands Oncology Group, PA - North Hills
Springdale, Arkansas
California Cancer Associates for Research and Excellence (CCARE)-Fresno
Fresno, California
UCSF Medical Center at Mission Bay
San Francisco, California
Yale Cancer Center
New Haven, Connecticut
AdventHealth Celebration
Celebration, Florida
AdventHealth Orlando
Orlando, Florida
Emory Saint Joseph's Hospital
Atlanta, Georgia
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Siteman Cancer Center - Washington University Medical Campus
St Louis, Missouri
Northwell Health - Centers for Advanced Medicine
Lake Success, New York
University of Rochester
Rochester, New York
Messino Cancer Centers
Asheville, North Carolina
Gabrail Cancer Research Center
Canton, Ohio
Allegheny General Hospital
Pittsburgh, Pennsylvania
Virginia Cancer Specialists - Fairfax
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.